Introduction The availability of over-the-counter (OTC) medicines containing codeine has generated worldwide debate with increased focus on its safe use. Medicine agencies across the European Union (EU) have responded to the public health concern by placing restrictions and warnings on codeine medicines sold OTC in High Street and internet pharmacies. These restrictions include direct-to-consumer advertising; however, there are few published studies examining conditions of advertising across member states. Methods A review of the conditions of advertising was conducted by accessing information pertaining to each medicine's regulatory agency allowing the sale of codeine in the EU. Each agency was asked to respond to three topics: (1) level and type of restrictions placed on all forms of direct-to-consumer advertising of OTC medicines containing codeine; (2) labelling criteria on packaging including indication related to the risk of addiction and any other patient information specific to codeine; and (3) complaints received by the medicines agency related to direct consumer advertising of OTC medicines containing codeine. Data were collated and tabulated in Excel to demonstrate its position on OTC codeine advertising. Results In the EU, 12 countries allow the sale of OTC codeine, while 16 do not. Of the 12 countries permitting its sale OTC, 4 countries prohibited direct-to-consumer advertising of codeine. The majority of the countries permitting advertisements did not have any additional or special restrictions or warnings for codeine-containing products with the exception of the UK where advertising codeine was only permitted under certain restrictions including product endorsement and special warnings including its indication of use for a maximum of 3 days. Conclusion There is wide disparity in advertising of OTC codeine in the EU. Safeguards for OTC codeine use are likely to continue to remain a priority in the interest of public safety.
Introduction
The availability of over-the-counter (OTC) medicines containing codeine has generated worldwide debate with increased focus on its safe use [1] [2] [3] . Data on codeine use and misuse across the European Union (EU) remain scant and confined to French and Norwegian studies with some statistics available on substance use disorder (SUD) treatment in the UK and Ireland [4] [5] [6] [7] . In the UK in 2013-2014, 2.2% of individuals attending specialist addiction treatment services did so for codeine. In Ireland over a defined 5-year period, 1.7% of all people attending treatment did so for codeine.
Codeine is an appropriate medicine used in the shortterm treatment of mild-to-moderate pain; however, due to risk of developing an addiction, use for chronic pain in the longer term may result in the consumption of higher-thanrecommended doses for longer than is medically advisable [8] . There is also risk of harmful effects resulting from prolonged-or over-use of paracetamol, ibuprofen and aspirin contained in many combination codeine products [9] [10] [11] . The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM V) currently defines 'addiction' under the term substance use disorder (SUD). Under this term the diagnosis of a SUD is based on a set of behaviours related to the use of that substance and falls into four main categories. These categories included impaired control, social impairment, risky use and pharmacological indicators such as tolerance and withdrawal.
National medicine agencies across the EU have responded to the public health concern by placing restrictions and warnings on codeine medicines sold OTC in High Street and internet pharmacies. These restrictions include the availability of codeine for self-selection (without requesting it directly from the pharmacist), limits on quantities purchased in a single transaction and drug potency [12] . Previous research in 2015 has shown that 12 of the 28 EU member states allowed the sale of OTC codeine in solid dosage form (Bulgaria, Cyprus, Denmark, Estonia, Ireland, Latvia, Lithuania, Malta, Poland, France, Slovenia and the UK) and two countries (the Netherlands and Hungary) as a codeine cough linctus only. Denmark was the only member state allowing the sale of OTC codeine in supermarkets and convenience stores (behind the counter).
Recently, direct-to-consumer advertising of OTC codeine has come under the spotlight as having the potential to influence buying behaviour [2] . Advertising of medicine is defined in medical law as "any form of door to door information, canvassing activity or inducement designed to promote the prescription, supply, sale or consumption of medicinal products" [13] . This specifically includes advertising to the general public, supply of samples, inducements to prescribe or supply by the gift, offer or promise of a bonus, monetary remuneration in any form, and sponsorships including travel or accommodation associated with medical conferences or medicine selling.
Direct-to-consumer advertising of OTC medicines remains controversial [14, 15] . Some argue it is specifically designed to convince the consumer that the product is worth buying and will have a beneficial effect on health, with opponents claiming it misleads consumers into buying drugs they may not necessarily need or want. Counter-claims to the debate argue that advertising of OTC medicines add a highly valued source of information to allow consumers to make informed decisions about self-care for pain relief [15] .
Direct-to-consumer advertising of prescription drugs is illegal in the EU. However, it is suggested that consumers often access online content and view branded drug websites in the USA and New Zealand where direct-to-consumer advertising of prescription drugs is legal [16] .
To date, there has been limited research examining regulatory conditions related to the advertising of OTC medicines containing codeine to the public across the EU. The aim of this study was to describe the regulatory position on the advertising of codeine for sale OTC in each of the EU member states permitting its sale to the public without a medical prescription, specifically to (i) identify which countries allowed direct advertising of OTC medicines containing codeine and (ii) if the harms imposed by codeine consumption were adequately communicated, and aimed to prevent unnecessary patient exposure to risk of developing a SUD.
Methods
Data were collected between September 2017 and February of 2018. Initially, current regulation on the sale of OTC codeine was established for each of the EU member states. First, the website of each of the relevant medicines agencies was searched over a 2-week period at the beginning of the study. Each website was screened using the English language option. The objective of the web search was to establish if codeine was permitted for sale OTC and to check for information relating to the advertising of OTC medicines. Second, agencies were contacted by e-mail to obtain specific information related to direct-to-consumer advertising of codeine. Medicines agencies not responding by e-mail within a 6-week time frame (Denmark, France, Bulgaria and Slovenia) were followed up by telephone call by one of the research team members. All medicines agencies made a reply giving a 100% response rate.
A topic guide was devised to guide the data collection and to ensure that comparisons could be made. Three subject areas were included: (1) level and type of restrictions placed on all forms of direct-to-consumer advertising of OTC medicines containing codeine; (2) labelling criteria on packaging including indication related to the risk of addiction and any other patient information specific to codeine; and (3) complaints received by the medicines agency related to direct consumer advertising of OTC medicines containing codeine.
Data were collated and summarised and entered into an Excel ® spreadsheet. Two members of the research team independently tabulated the data under each of the three main topics. The content of this information was discussed, crosschecked and agreed before compiling two tables [17] . A third member of the research team checked the content of the final table and reviewed the data against the written content received by 11 of the 12 countries. One country (Bulgaria) had not provided a written response so verbal responses noted by the researcher were checked in this case. Table 1 shows the permitted sales of OTC codeine medicines in the EU. Recent rescheduling of codeine has occurred in two European countries. In 2015 Hungary removed the sale of codeine cough mixture for sale without a medical prescription and in 2017 France restricted codeine to prescription only [18] . Twelve countries allow the sale of OTC codeine, while 16 do not. Table 2 shows the conditions of advertising, packaging requirements of OTC codeine and if complaints were received by the medicine agency. Of the 12 countries permitting its sale OTC, 4 countries prohibited direct-to-consumer advertising of codeine. All countries highlighted that direct-to-consumer advertising of medicines was stipulated in the Medicines Act of that country. The majority of the countries permitting advertising had no additional or special restrictions or warnings for codeinecontaining products with the exception of the UK where advertising codeine was only permitted under certain restrictions relating to product endorsement and special warnings, including its indication of use for a maximum of 3 days. Equally, the UK was the only country stipulating advertising warnings with respect to the risk of developing an addiction. The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK was the only agency indicating advertising complaints made by members of the public. This was related to two OTC codeine products, Syndol ® and Solpadeine ® Max. It was claimed that promotional materials for Syndol ® were inadequate and the latter complaint relating to Solpadeine ® Max suggested that warnings around use of codeine were not clearly presented. In both cases the MHRA did not uphold the complaint but did however make recommendations resulting in changes to advertising of both products.
Results

Conditions of Codeine Advertising across the EU
Discussion
The study found wide disparity in direct-to-consumer advertising of OTC codeine across the EU. It is likely that countries banning the advertising of codeine perceive the risks to be greater than those that did not, including the potential for consumers to develop a SUD from inappropriate codeine use. For some countries like Denmark and the UK, allowing direct-to-consumer advertisement may hold the opposite viewpoint, either that adequate structures are already in place to prevent excessive use, or that the levels of codeine contained in OTC formulations are too small to induce a SUD [2] .
Across EU member states, there appears to be a lack of evidence to evaluate the effects of codeine advertising on consumers' decision to purchase, consumption patterns or levels of SUD. However, television advertisements are considered to be an important promotional tool on potential buyers of medicines, particularly analgesics. Non-opioid analgesics are some of the most popular OTC medicines purchased across Europe, and studies have shown that television advertising has a significant impact on purchase decisions [15] . Marketing strategies such as that adopted by Purdue Pharma ® for promoting OxyContin ® directly to doctors was shown to play a huge role in the opioid epidemic in the USA [19] . The concern would be that promoting codeine directly to the public through any form of advertisement may play a role in medicine use and subsequently the development of a SUD. Additionally, online promotional advertising of prescription medicines accessible globally presents additional challenges for national regulatory agencies not permitting direct-to-consumer advertising of medicines either prescription or OTC. While traditional print and broadcast media can be controlled to a certain extent, online promotions have the ability to cross national boundaries through various media platforms to countries when it is not legal [16] . Of the countries allowing direct-to-consumer advertising, the UK appears to be the most comprehensive in communicating risk of developing an addiction in advertising materials to the public, although some complaints were received. While the impact of such communication remains unquantifiable, other countries permitting directto-consumer advertising should consider improvements in communication to highlight the risks of SUD in the interest of public health. Studies have shown that content contained in advertisements can change perceptions surrounding the drug's efficacy, risk and benefit [20] . The current study did not review if the advertisements met the conditions of the competent authorities and while it was stipulated that all advertising materials must be comprehensive, valid and include information like the product name, active ingredients, adverse drug reactions, precautions and contraindications, it is likely that inclusions of health warnings on packaging and improvements in patient-information leaflets (PILs) could further educate the public on safe use and potential risk of SUD. It should be noted that all medicines must, under EU regulation, include PILs providing information on the safe and appropriate use of the medicine. However, studies have shown that patients often fail to read and/or understand the information provided in the PIL [21] . It is also important in the future to establish if direct sale of OTC codeine in countries with fewer restrictions of sale correlate with national figures for codeine-specific SUD, adverse drug reactions, intoxication and mortality. Codeine consumption resulting in SUD is now recognised around the world as a serious problem [22] and shows the importance of reviewing and challenging current regulation. From the perspective of drug safety and risk management, it is important to investigate fully the impact of codeine advertising on developing a SUD.
One of the limitations of the study is that it did not evaluate the advertising materials from the eight countries permitting the advertising of codeine OTC. Therefore, we are unable to comment directly on the content of advertising in each member state. All countries were accessed in the English language and there is some possibility that information could have been lost through translation and other relevant information may have been available that was published in the local language. However, all responses given by the competent authority in each country were done through the English language.
Conclusions
The condition of sale and advertising of OTC codeine and its association with developing a SUD is likely to remain a subject of popular debate into the future. Safeguards are likely to continue to remain a priority in the interest of public safety in many EU member states and worldwide. Strengthening medicine safety is a key priority for the European Medicines Agency and direct-to-consumer advertising of codeine in countries allowing its sale without direct medical supervision needs to be further examined to ensure it is adequate and is not placing consumers at increased harm.
